Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19712383 | 0.88 | MDM2 (0.39) | MEN1KMT2ADRD4MDM2PPARA | |
| SCHEMBL2128204 | 0.87 | MEN1 (0.45) | MEN1KMT2ADRD4MDM2PPARA | |
| SCHEMBL30794831 | 0.87 | MEN1 (0.45) | MEN1KMT2ADRD4MDM2PPARA | |
| SCHEMBL2128658 | 0.85 | MEN1 (0.43) | MEN1KMT2ADRD4PPARAPDE5A | |
| SCHEMBL2130019 | 0.85 | MEN1 (0.43) | MEN1KMT2ADRD4PPARAPDE5A | |
| SCHEMBL2131202 | 0.85 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2RAB9ALMNA | |
| SCHEMBL2131613 | 0.83 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2RAB9ALMNA | |
| SCHEMBL19712373 | 0.78 | MEN1 (0.39) | MEN1KMT2ADRD4MDM2PPARA | |
| SCHEMBL2132122 | 0.78 | MEN1 (0.48) | MEN1KMT2AMDM2SMN1; SMN2RAB9A | |
| SCHEMBL2128937 | 0.78 | MEN1 (0.49) | MEN1KMT2ASMN1; SMN2RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630123-B1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2017-12-20 | — | — | EP | claimed |
| US-9278103-B2 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2016-03-08 | — | — | US | claimed |
| US-20140213569-A1 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2014-07-31 | — | — | US | claimed |
| EP-2630123-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-08-28 | — | — | EP | claimed |
| US-20120258947-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-10-11 | — | — | US | claimed |
| US-20120101079-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-04-26 | — | — | US | claimed |
| WO-2012052167-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-04-26 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-3318556-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2018-05-09 | — | — | EP | disclosed |
| US-20120258947-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120258947-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120258947-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120101079-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
| US-20120101079-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
| US-20120101079-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
| WO-2012052167-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213569-A1 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | KCNQ2, KCNQ1, KCNQ3 | MEN1 3018/4885KMT2A 403/4885DRD4 3937/4885 |
| US-20120101079-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ2, KCNQ1, KCNQ3 | MEN1 3018/4885KMT2A 403/4885DRD4 3937/4885 |
| US-20120258947-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ2, KCNQ1, KCNQ3 | MEN1 3018/4885KMT2A 403/4885DRD4 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.